{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T11:03:30Z","timestamp":1789383810194,"version":"build-2803163510"},"reference-count":15,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Healthcare"],"abstract":"<jats:p>Background: The evidence is still sparse on the effects of various doses and routes of buprenorphine on emotional and clinical outcomes for individuals with OUD. Methods: A systematic review and meta-analysis of RCTs was performed following PRISMA and Cochrane guidelines. The electronic databases and other sources were searched for studies that were published from February 2013 to September 2025. Negative emotional symptomology, illicit opioid use, treatment retention, and adverse events were eligible outcomes. Standardized mean differences and odds ratios were used to summarize continuous and binary outcomes, respectively. Results: There were five RCTs that met the inclusion criteria. In studies comparing single-dose buprenorphine, a single dose of 96 mg was more effective than a single dose of 32 mg on negative emotional symptom scores (SMD = \u22120.66, 90% CI [\u22121.00, \u22120.32]). But limited evidence suggested that the odds of observing illicit opioid use were lower with subcutaneous buprenorphine than sublingual buprenorphine (OR = 0.61, 90% CI [0.39, 0.94]). There were no apparent differences between dose comparisons or administration-route comparisons with respect to adverse events. Levels of certainty of evidence were relatively low. Conclusions: Some limited data suggest there may be a correlation between the dose and route of buprenorphine administration and short-term emotional and illicit opioid-use outcomes. But the number of trials, the size of the samples, and methodological flaws significantly limit the validity and applicability of these results. It is worth emphasising that the high-dose comparisons featured in this review were from single doses in acute treatment settings, and thus are not suitable for extrapolating to everyday, maintenance doses.<\/jats:p>","DOI":"10.3390\/healthcare14182995","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T09:34:01Z","timestamp":1789378441000},"page":"2995","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dosage and Administration-Related Emotional and Clinical Outcomes of Buprenorphine Treatment for Opioid Use Disorder: A Systematic Review and Meta-Analysis"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1447-3652","authenticated-orcid":false,"given":"Yunyi","family":"Xiao","sequence":"first","affiliation":[{"name":"School of Politics and Law, Hanshan Normal University, Chaozhou 521041, China"},{"name":"School of Social Policy, University of Birmingham, Birmingham B15 2TT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Ribeiro","family":"Ramos","sequence":"additional","affiliation":[{"name":"School of Social Policy, University of Birmingham, Birmingham B15 2TT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8008-1370","authenticated-orcid":false,"given":"Paul","family":"Montgomery-Marks","sequence":"additional","affiliation":[{"name":"School of Social Policy, University of Birmingham, Birmingham B15 2TT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"ref_1","unstructured":"National Institute on Drug Abuse (2026, March 01). What Are Misconceptions About Maintenance Treatment?, Available online: https:\/\/nida.nih.gov\/publications\/research-reports\/medications-to-treat-opioid-addiction\/what-are-misconceptions-about-maintenance-treatment."},{"key":"ref_2","unstructured":"World Health Organization (2009). Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence, WHO."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4103\/0976-3147.91934","article-title":"Buprenorphine vs. methadone treatment: A review of evidence in both developed and developing worlds","volume":"3","author":"Whelan","year":"2012","journal-title":"J. Neurosci. Rural Pract."},{"key":"ref_4","unstructured":"Kumar, R., Viswanath, O., and Saadabadi, A. (2026, March 01). Buprenorphine, StatPearls, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK459126\/."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"445","DOI":"10.4103\/0253-7176.211765","article-title":"Anxiety treatment of opioid dependent patients with buprenorphine: A randomized, double-blind, clinical trial","volume":"39","author":"Ahmadi","year":"2017","journal-title":"Indian J. Psychol. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1186\/s13063-018-2843-9","article-title":"The effectiveness of different singly administered high doses of buprenorphine in reducing suicidal ideation in acutely depressed people with co-morbid opiate dependence: A randomized, double-blind, clinical trial","volume":"19","author":"Ahmadi","year":"2018","journal-title":"Trials"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Mattick, R.P., Breen, C., Kimber, J., and Davoli, M. (2014). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst. Rev., CD002207.","DOI":"10.1002\/14651858.CD002207.pub4"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e219041","DOI":"10.1001\/jamanetworkopen.2021.9041","article-title":"Patient-reported outcomes of treatment of opioid dependence with weekly and monthly subcutaneous depot vs daily sublingual buprenorphine: A randomized clinical trial","volume":"4","author":"Lintzeris","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_9","first-page":"CD007210","article-title":"Maintenance treatments for opiate-dependent adolescents","volume":"2014","author":"Minozzi","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_11","unstructured":"Higgins, J.P., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M.J., and Welch, V.A. (2022). Cochrane Handbook for Systematic Reviews of Interventions, Cochrane. Available online: https:\/\/training.cochrane.org\/handbook."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jsat.2014.06.006","article-title":"Buprenorphine pharmacotherapy and behavioral treatment: Comparison of outcomes among prescription opioid users, heroin users and combination users","volume":"48","author":"Nielsen","year":"2015","journal-title":"J. Subst. Abus. Treat."},{"key":"ref_13","unstructured":"Sch\u00fcnemann, H.J., Vist, G.E., Higgins, J.P., Santesso, N., Deeks, J.J., Glasziou, P., Akl, E.A., and Guyatt, G.H. (2024). Chapter 15: Interpreting results and drawing conclusions. Cochrane Handbook for Systematic Reviews of Interventions, Cochrane. Version 6.5."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1186\/s13063-018-3055-z","article-title":"Single high-dose buprenorphine for opioid craving during withdrawal","volume":"19","author":"Ahmadi","year":"2018","journal-title":"Trials"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1001\/jama.2016.9382","article-title":"Effect of buprenorphine implants on illicit opioid use among abstinent adults with opioid dependence treated with sublingual buprenorphine: A randomized clinical trial","volume":"316","author":"Rosenthal","year":"2016","journal-title":"JAMA"}],"container-title":["Healthcare"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9032\/14\/18\/2995\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T10:09:11Z","timestamp":1789380551000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9032\/14\/18\/2995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":15,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["healthcare14182995"],"URL":"https:\/\/doi.org\/10.3390\/healthcare14182995","relation":{},"ISSN":["2227-9032"],"issn-type":[{"value":"2227-9032","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]}}}